MarginsXMarginsX
Home › Markets › Health Care › BLSM

BlossomHill Therapeutics Inc. (BLSM)

BLSM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$13.65
-2.64% on the day
Market cap
$433.9M
Small cap
Revenue
New registrant: no annual report filed under this company yet
Net income
New registrant: no annual report filed under this company yet

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerBLSM on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2026
SEC CIK0001839970
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

New registrant: no annual report filed under this company yet.

Warning signs

Cash runway
40.0 months
$224.9M cash at September 30, 2026
Share count, 1 year
No year-earlier count
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
$15.2M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$224.9M cash; operating cash flow -$16.9M a quarter.Report 2026-09-30
Shares outstanding31,784,909 (2026-11-10).Cover page 2026-11-10
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, San Diego, California, United StatesPCAOB Form AP 2026-08-06
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $15.2M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$24.0M-$22.2M$224.9MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2026
2026-06-30
Not filed-$23.8MNot filed$95.4MNo debt tagsNeeds four quarters10-Q 2026-09-18
Q3 2026
2025-09-30
Not filed-$16.0M-$11.6M$67.8MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2026
2025-06-30
Not filed-$13.2MNot filed$79.1MNo debt tagsNeeds four quarters10-Q 2026-09-18

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B42026-08-07
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12

Source: SEC EDGAR submissions feed, 48 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+3.9%
1 month-9.4%
3 months-14.3%
Year to dateNot enough price history
1 yearNot enough price history
From 52-week high-47.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CTMXCytomX Therapeutics Inc.$1.99-2.70%$432.7M
ASMBAssembly Biosciences Inc.$21.29+0.80%$436.0M
EOLSEvolus Inc.$6.63-4.74%$438.8M
AVTXAvalo Therapeutics Inc.$7.37-5.03%$426.2M
ARVNArvinas Inc.$6.77-0.73%$443.3M
MPLTMapLight Therapeutics Inc.$6.90-4.83%$446.9M
DMACDiaMedica Therapeutics Inc.$8.33-5.23%$449.5M
OVIDOvid Therapeutics Inc.$2.40-5.51%$453.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier